{"id":"hydrocortisone-fludrocortisone","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hypokalemia"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Infection (secondary)"},{"rate":null,"effect":"Gastrointestinal bleeding"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Hydrocortisone is a glucocorticoid that suppresses inflammation and regulates metabolism, while fludrocortisone is a mineralocorticoid that promotes sodium retention and potassium excretion to maintain blood pressure and electrolyte balance. Together, they replace the hormonal deficiency seen in adrenal insufficiency or critical illness-related corticosteroid insufficiency (CIRCI).","oneSentence":"This combination of hydrocortisone and fludrocortisone replaces deficient glucocorticoid and mineralocorticoid hormones to restore adrenal function.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:55:05.029Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Septic shock with adrenal insufficiency"},{"name":"Critical illness-related corticosteroid insufficiency (CIRCI)"}]},"trialDetails":[{"nctId":"NCT06136650","phase":"PHASE3","title":"A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-18","conditions":"Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms","enrollment":1314},{"nctId":"NCT06136624","phase":"PHASE3","title":"Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-31","conditions":"Prostate Cancer Metastatic","enrollment":1310},{"nctId":"NCT06136598","phase":"PHASE1","title":"A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-01-30","conditions":"Prostatic Neoplasms, Metastatic Castration-Resistant Prostate Cancer","enrollment":14},{"nctId":"NCT06979596","phase":"PHASE2","title":"A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-08-11","conditions":"Malignant Neoplasm","enrollment":250},{"nctId":"NCT06104449","phase":"PHASE1","title":"A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-11-14","conditions":"Prostatic Neoplasms, Metastatic Castration-Resistant Prostate Cancer","enrollment":6},{"nctId":"NCT07451886","phase":"PHASE2","title":"Adjunctive Fludrocortisone in Septic Shock","status":"NOT_YET_RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2026-04-01","conditions":"Sepsis, Septic Shock, Sepsis - to Reduce Mortality in the Intensive Care Unit","enrollment":32},{"nctId":"NCT07383103","phase":"PHASE4","title":"Hydrocortisone and Fludrocortisone for the Treatment of Septic Shock","status":"RECRUITING","sponsor":"Northern Jiangsu People's Hospital","startDate":"2026-03-02","conditions":"Septic Shock","enrollment":336},{"nctId":"NCT05440851","phase":"NA","title":"Platform of Randomized Adaptive Clinical Trials in Critical Illness","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2023-04-30","conditions":"Respiratory Insufficiency, Extracorporeal Membrane Oxygenation Complication, Mechanical Ventilation Pressure High","enrollment":6250},{"nctId":"NCT06381661","phase":"PHASE2","title":"Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-05-01","conditions":"Sepsis","enrollment":2000},{"nctId":"NCT06409364","phase":"PHASE2","title":"FLudrocortisone Administration in Aneurysmal Subarachnoid Haemorrhage","status":"RECRUITING","sponsor":"The George Institute","startDate":"2025-08-13","conditions":"Aneurysmal Subarachnoid Hemorrhage","enrollment":524},{"nctId":"NCT02574910","phase":"PHASE1","title":"Androgen Reduction in Congenital Adrenal Hyperplasia, Phase 1","status":"TERMINATED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2017-08-01","conditions":"Congenital Adrenal Hyperplasia","enrollment":4},{"nctId":"NCT04280497","phase":"NA","title":"Rapid Recognition of Corticosteroid Resistant or Sensitive Sepsis","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-04-10","conditions":"Sepsis","enrollment":1800},{"nctId":"NCT06649409","phase":"PHASE1","title":"Evaluation of Vamorolone Mineralocorticoid Receptor Antagonism in Healthy Subjects","status":"COMPLETED","sponsor":"Santhera Pharmaceuticals","startDate":"2024-06-05","conditions":"Pharmacodynamic","enrollment":30},{"nctId":"NCT07037043","phase":"PHASE3","title":"Hydrocortisone Plus Fludrocortisone in High-risk Patients Undergoing for Cardiac Surgery","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2025-08","conditions":"Inflammation in Cardiac Surgery","enrollment":196},{"nctId":"NCT00001521","phase":"PHASE3","title":"Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia","status":"COMPLETED","sponsor":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","startDate":"1995-06-08","conditions":"Congenital Adrenal Hyperplasia (CAH)","enrollment":66},{"nctId":"NCT04404400","phase":"PHASE3","title":"Hydrocortisone and Fludrocortisone for Critical Illness-related Corticosteroid Insufficiency","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-02-17","conditions":"Critical Illness Related Corticosteroids Insufficiency","enrollment":1092},{"nctId":"NCT05310253","phase":"NA","title":"Stress & Social Cognition in BPD (part 2)","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2022-02-01","conditions":"Borderline Personality Disorder","enrollment":240},{"nctId":"NCT06566989","phase":"PHASE1","title":"A Study of the Absorption, Distribution, Metabolism, and Elimination of Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-008)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-09-19","conditions":"Metastatic Prostate Cancer","enrollment":8},{"nctId":"NCT05001854","phase":"PHASE2, PHASE3","title":"Hemodynamics Effects of Fludrocortisone on the Pressor Response to Noradrenaline Septic Shock Patients","status":"SUSPENDED","sponsor":"Rennes University Hospital","startDate":"2022-03-31","conditions":"Septic Shock","enrollment":40},{"nctId":"NCT03773822","phase":"PHASE3","title":"Low Dose of Hydrocortisone and Fludrocortisone in Adult Cardiogenic Shock.","status":"COMPLETED","sponsor":"CMC Ambroise Paré","startDate":"2019-04-19","conditions":"Cardiogenic Shock","enrollment":380},{"nctId":"NCT04128137","phase":"PHASE4","title":"Efficacy and Tolerance of Flucortac in Patients With Orthostatic Neurogenic Hypotension","status":"UNKNOWN","sponsor":"H.A.C. PHARMA","startDate":"2020-07-09","conditions":"Neurogenic Orthostatic Hypotension","enrollment":90},{"nctId":"NCT03548246","phase":"PHASE2","title":"Androgen Reduction in Congenital Adrenal Hyperplasia","status":"WITHDRAWN","sponsor":"University of Texas Southwestern Medical Center","startDate":"2023-01","conditions":"Congenital Adrenal Hyperplasia","enrollment":""},{"nctId":"NCT02871648","phase":"PHASE1","title":"The Role of Minerelocorticoid Receptor on Modulating Aldosterone Production","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2016-01","conditions":"Healthy Volunteers","enrollment":23},{"nctId":"NCT03710187","phase":"PHASE2","title":"HCT+F vs. HCT Alone in Critically Ill Medical Septic Shock Patients","status":"COMPLETED","sponsor":"University of Tennessee Medical Center","startDate":"2018-11-05","conditions":"Septic Shock","enrollment":84},{"nctId":"NCT03001089","phase":"PHASE2","title":"Impact of the Administration of Fludrocortisone in Very Premature Infants","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-06-01","conditions":"Partial Mineralocorticoid Deficiency","enrollment":66},{"nctId":"NCT01993680","phase":"PHASE2","title":"Orthostatic Dysregulation and Associated Gastrointestinal Dysfunction in Parkinson's Disease -Treatment","status":"COMPLETED","sponsor":"Christian Baumann","startDate":"2012-06","conditions":"Autonomic Disturbances in Parkinson's Disease","enrollment":18},{"nctId":"NCT04492280","phase":"PHASE4","title":"Evaluation of the Role of Hydrocortisone Either Alone or Combined With Fludrocortisone in the Outcome of Septic Shock in Adults","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2018-09-01","conditions":"Septic Shock","enrollment":66},{"nctId":"NCT03062150","phase":"NA","title":"Mineralocorticoid Receptor, NMDA Receptor and Cognitive Function in Depression","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2016-09-27","conditions":"Major Depression","enrollment":232},{"nctId":"NCT01186185","phase":"EARLY_PHASE1","title":"Fludrocortisone for Sudden Hearing Loss","status":"TERMINATED","sponsor":"Oregon Health and Science University","startDate":"2012-08","conditions":"Hearing Loss, Sensorineural","enrollment":5},{"nctId":"NCT01690039","phase":"","title":"Influence of Polymorphisms in the ATP6V1 Gene of the V-ATPase on the Development of Incomplete Distal Renal Tubular Acidosis","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2012-09","conditions":"Acidosis, Renal Tubular, Nephrolithiasis, Vacuolar Proton-Translocating ATPases","enrollment":170},{"nctId":"NCT02140918","phase":"PHASE2","title":"Fludrocortisone in Healthy Volunteers (AFLUCO4)","status":"COMPLETED","sponsor":"Rennes University Hospital","startDate":"2014-07-01","conditions":"Healthy Volunteers","enrollment":16},{"nctId":"NCT01093261","phase":"PHASE3","title":"Corticosteroid Therapy for Glucocorticoid Insufficiency Related to Traumatic Brain Injury","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2010-08","conditions":"Traumatic Brain Injury, Trauma, Adrenal Insufficiency","enrollment":336},{"nctId":"NCT00625209","phase":"PHASE3","title":"Activated Protein C and Corticosteroids for Human Septic Shock","status":"COMPLETED","sponsor":"University of Versailles","startDate":"2008-03","conditions":"Septic Shock","enrollment":1241},{"nctId":"NCT00295347","phase":"NA","title":"Mineralocorticoid Receptor in the Treatment of Severe Depression","status":"COMPLETED","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2005-12","conditions":"Major Depression","enrollment":65},{"nctId":"NCT02532998","phase":"PHASE1","title":"A Study to Assess the Pharmacodynamic Effect of Single Doses of AZD9977 in Healthy Male Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-09","conditions":"Pharmacodynamics, Healthy Subjects","enrollment":40},{"nctId":"NCT02478034","phase":"NA","title":"Effects of Mineralocorticoid Receptor Stimulation on Cognition","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2015-05","conditions":"Individuality","enrollment":80},{"nctId":"NCT00608101","phase":"NA","title":"Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus","status":"WITHDRAWN","sponsor":"Vanderbilt University","startDate":"2010-09","conditions":"Type 1 Diabetes","enrollment":""},{"nctId":"NCT00623766","phase":"PHASE2","title":"Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2008-07","conditions":"Melanoma","enrollment":99},{"nctId":"NCT01648998","phase":"PHASE1","title":"Fludrocortisone and Information Processing in Healthy Volunteers","status":"COMPLETED","sponsor":"Leiden University Medical Center","startDate":"2012-05","conditions":"Depression","enrollment":40},{"nctId":"NCT02069288","phase":"PHASE3","title":"Effects of Fludrocortisone on Norepinephrine-mean Arterial Pressure Dose-response in Septic Shock","status":"WITHDRAWN","sponsor":"Rennes University Hospital","startDate":"","conditions":"Septic Shock","enrollment":""},{"nctId":"NCT00673270","phase":"PHASE1, PHASE2","title":"Effects of Fludrocortisone and Hydrocortisone in Healthy Volunteers With Aldosterone Induced Suppression","status":"TERMINATED","sponsor":"Rennes University Hospital","startDate":"2008-05","conditions":"Renin Angiotensin","enrollment":13},{"nctId":"NCT00368381","phase":"PHASE4","title":"Hydrocortisone Versus Hydrocortisone Plus Fludrocortisone for the Treatment of Adrenal Insufficiency in Severe Sepsis","status":"WITHDRAWN","sponsor":"CAMC Health System","startDate":"2006-09","conditions":"Sepsis, Adrenal Insufficiency","enrollment":""},{"nctId":"NCT01453959","phase":"PHASE4","title":"Fludrocortisone's Test in Salt Sensitivity","status":"UNKNOWN","sponsor":"Fundação de Amparo à Pesquisa do Estado de São Paulo","startDate":"2011-07","conditions":"Hypertension","enrollment":40},{"nctId":"NCT00320099","phase":"PHASE3","title":"Combination of Corticotherapy and Intensive Insulin Therapy for Septic Shock","status":"COMPLETED","sponsor":"University of Versailles","startDate":"2006-01","conditions":"Septic Shock","enrollment":508},{"nctId":"NCT00103597","phase":"PHASE1","title":"Efficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson's Disease and Multiple System Atrophy","status":"COMPLETED","sponsor":"Royal Brisbane and Women's Hospital","startDate":"2005-01","conditions":"Parkinson's Disease, Multiple System Atrophy, Orthostatic Hypotension","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":24,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Hydrocortisone Fludrocortisone","genericName":"Hydrocortisone Fludrocortisone","companyName":"Nantes University Hospital","companyId":"nantes-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination of hydrocortisone and fludrocortisone replaces deficient glucocorticoid and mineralocorticoid hormones to restore adrenal function. Used for Septic shock with adrenal insufficiency, Critical illness-related corticosteroid insufficiency (CIRCI).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}